This combination includes Empagliflozin (SGLT2 inhibitor) and Linagliptin (DPP-4 inhibitor). It is indicated for the treatment of type 2 diabetes mellitus. Empagliflozin promotes urinary glucose excretion, while Linagliptin enhances incretin hormone activity, increasing insulin secretion and reducing glucagon levels.
Reviews
There are no reviews yet.